PepGen (PEPG) announced initial clinical data from the five and ten mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1. Mean splicing ...
PBGENE-HBV was safe and well tolerated at 0.2 mg/kg, with no serious adverse events in cohort 1 of the ELIMINATE-B trial. Two of three participants showed a substantial reduction in HBsAg after ...
The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg/kg cohorts, respectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback